PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics
19 sept. 2024 09h00 HE
|
Renovaro Inc
AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven,...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
19 sept. 2024 08h00 HE
|
AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
KnitWell Group Supports the Breast Cancer Research Foundation With Eight Iconic American Retail Fashion Brands Through Their Sisterhood of Strength Campaign
18 sept. 2024 15h25 HE
|
D S Simon
NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- In honor of Breast Cancer Awareness Month, a leading multi-brand retail operating company, KnitWell Group, comprised of Ann Taylor, Chico’s, Haven Well...
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
18 sept. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
18 sept. 2024 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
Wistar Institute Researchers Identify Parkinson-related Protein’s Role in Cancer and T Cell Activation
17 sept. 2024 12h54 HE
|
The Wistar Institute
PHILADELPHIA, PA, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Wistar Institute’s President and CEO, Dario C. Altieri, M.D., and team have demonstrated the role of Parkin — a protein implicated in...
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
17 sept. 2024 09h00 HE
|
Renovaro Inc
AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation...
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
17 sept. 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR
17 sept. 2024 06h00 HE
|
FACT.MR
Rockville, MD, Sept. 17, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global chemotherapy induced nausea and vomiting treatment...
Eisbach Bio Announces First Patient Dosed in Phase 1/2 Trial for EIS-12656, a First-In-Class Allosteric Inhibitor of ALC1 in Refractory Advanced Solid Tumors
16 sept. 2024 07h00 HE
|
Eisbach Bio GmbH
The first patient has been dosed in Eisbach Bio’s Phase 1/2 MATCH clinical trial at MD Anderson assessing the ALC1 inhibitor EIS-12656 in solid tumors.